138  0 Kommentare Admedus Changes Name to Anteris Technologies Ltd

Provides Corporate and Clinical Development Update

BRISBANE, Australia and EAGAN, Minn., June 01, 2020 (GLOBE NEWSWIRE) -- Admedus Limited (ASX: AHZ), announced today that it has changed the Company’s name to Anteris Technologies Ltd (“Anteris”). As of May 22, 2020 Anteris, is trading on the Australian Securities Exchange under the ticker AVR. This milestone signifies the completion of Admedus’ restructuring program focused on transitioning to a dedicated structural heart company anchored by ADAPT, a next generation regenerative bioscaffold platform technology being utilized to address multiple cardiovascular procedures and repairs including, a product (DurAVR) in development for Transfemoral Aortic Valve Replacement (TAVR) procedures.

“The name change marks the beginning of an exciting chapter in the Company’s growth plan as we are now well positioned to facilitate shareholder value creation,” commented Wayne Paterson, Chief Executive Officer of Anteris Technologies Ltd. “It culminates a three-year period devoted to streamlining operations while enhancing our leadership team, ceasing non-core therapeutic programs, and divesting low margin assets to enable absolute focus on advancing the development of our portfolio of game-changing products generated by the ADAPT platform.”

Lesen Sie auch

Q1-Zahlen überzeugen

Starke Nachfrage: Thermo Fisher hebt Gewinnprognose an

gestern 15:44

KI-Alternativen

Diese 6 Aktien lauern nur auf eine Schwäche von Nvidia, um zu steigen!

21.04.24, 07:07

Quartalszahlen

China sei Dank: Intuitive Surgical übertrifft Erwartungen, Aktie steigt!

19.04.24, 10:29

Ihre wichtigsten Termine

Frische Zahlen von: Netflix, L' Oréal, Nokia, Deliveroo, Ally Financial & Danone

18.04.24, 04:30

The key advantage of DurAVR based on the ADAPT technology, is its ability to solve the issues associated with current aortic valve replacement options. DurAVR is expected to have improved durability by preventing valve degradation through a combination of tissue science and valve design. ADAPT treated valves are built on the only known bioscaffold product to demonstrate “zero-calcification” even after 10 years of use in humans (tissue science). Its unique ability to be molded into a 3D single-piece structure (valve design), also demonstrates significantly less wear at the leaflets than conventional three-piece valves. By combining these two positive features, the valves are able to retain shape and preserve functionality over the long-term. Such a durable, long-lasting valve with the potential to not calcify or need to be replaced is ideal for expanding the TAVR market (already >$5B in sales) to a patient population which is becoming increasingly younger.